4th Quarter - Report

INDEPENDENT PHARMACY COOPERATIVE for INDEPENDENT PHARMACY COOPERATIVE

Period 4th Quarter 2024 Filed Jan 10, 2025 Signed by Mark Kinney

Official filing
Firm
INDEPENDENT PHARMACY COOPERATIVE
Client
INDEPENDENT PHARMACY COOPERATIVE
Income
—
Expenses
$40,000
Expense method
A: Lobbying Disclosure Act definitions

What was lobbied

One issue area, each in the filer's own words, with who lobbied on it and where.

Pharmacy PHA

IPC supports "Better Mental Health Care, Lower Cost Drugs and Extenders Act" (S 3430) IPC supports the "Pharmacists Fight Back Act" (HR 9096) IPC supports Drug Transparency in Medicaid Act (H.R. 1613) ICP supports Promoting Access to Treatments and Increasing Extremely Needed Transparent (PATIENT) Act (HR 3561) IPC supports Drug Transparency in Medicaid Act (S. 1038) IPC supports The Modernizing and Ensuring PBM Accountability Act (S 2973) IPC supports Pharmacy and Medically Underserved Areas Enhancement Act (S 1491) IPC supports Protecting Patients Access to Pharmacy Act (S. 2052) IPC supports The Health Care Price Transparency Act (H.R. 4822) IPC supports Lower Cost, More Transparency Act (LCMT) (H.R. 5378) IPC supports Protecting Patients Against PBM Abuses Act (H.R. 2880) IPC Transparency and Fairness for Pharmacies Act (H.R. 5393) IPC supports Senate Bi-Partisan Working Group for 340B Reform - RFI response. IPC Supports FDA - Development of Small Dispensers Assessment Under the Drug Supply Chain Security Act; Request for Comments (FDA-2023-N-3103) IPC supports the Inflation Reduction Act of 2022 and CMS implementation. IPC opposes S. 1339 Pharmacy Benefits Reform Act - because it may preempt state PBM laws relating to ERISA. IPC supports S. 1491 Pharmacy and Medically Underserved Areas Enhancement Act IPC supports S. 127 Pharmacy Benefit Manager Transparency Act IPC supports (H.R. 1770/S. 2477) The Equitable Community Access to Pharmacists Services Act IPC supports FDA delay of DSCSA enhanced data compliance-request for comments CMS Implementation of PY 2024 Medicare Part D drug rule-comments CMS Implementation of drug provisions of the IRA 2022-including the drug negotiation provision

LobbyistCovered position, as disclosed
JOHN A. COVELLO —
MARK EUGENE KINNEY —

Contacted: Centers For Medicare and Medicaid Services (CMS); Food & Drug Administration (FDA); SENATE; HOUSE OF REPRESENTATIVES

Bills named: H.R. 4822 (118th), H.R. 9096 (118th), S. 1038 (118th), S. 1491 (118th), S. 2052 (118th), H.R. 1770 (118th), S. 2477 (118th), H.R. 5393 (118th), H.R. 1613 (118th), S. 127 (118th), H.R. 3561 (118th), H.R. 2880 (118th), S. 1339 (118th), H.R. 5378 (118th)

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.